Alkermes Drug Patent Portfolio
Alkermes owns 4 orange book drugs protected by 56 US patents Given below is the list of Alkermes's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707466 | Immediate release multilayer tablet | 12 Nov, 2041 | Active |
| US11951111 | Immediate release multilayer tablet | 12 Nov, 2041 | Active |
| US12390474 | 12 Nov, 2041 | Active | |
| US11273158 | Aripiprazole dosing strategy | 06 Apr, 2039 | Active |
| US12251381 | Aripiprazole dosing strategy | 06 Apr, 2039 | Active |
| US10016415 | Aripiprazole prodrug compositions | 08 Sep, 2035 | Active |
| US10688091 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US10849894 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US11154552 | Aripiprazole prodrug composition | 17 Aug, 2035 | Active |
| US10238651 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US10813928 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US11406632 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US9452131 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US9526726 | Aripiprazole formulations having increased injection speeds | 19 Mar, 2035 | Active |
| US11097006 | Pharmaceutical compositions having improved storage stability | 24 Oct, 2033 | Active |
| US11969469 | 24 Oct, 2033 | Active | |
| US9193685 | Pharmaceutical compositions having improved storage stability | 24 Oct, 2033 | Active |
| US12311027 | 19 Sep, 2033 | Active | |
| US9034867 | Pharmaceutical compositions comprising sorbitan esters | 07 Nov, 2032 | Active |
| US10226458 | Pharmaceutical compositions comprising sorbitan esters | 19 Mar, 2032 | Active |
| US8778960 | Methods for treating antipsychotic-induced weight gain | 13 Feb, 2032 | Active |
| US9119848 | Morphinan derivatives for the treatment of drug overdose | 30 Aug, 2031 | Active |
| US10300054 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US10716785 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11185541 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11241425 | Composition for treating mental illness | 23 Aug, 2031 | Active |
| US11351166 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US11793805 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US12194035 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US9126977 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US9517235 | Methods for treating antipsychotic-induced weight gain | 23 Aug, 2031 | Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 26 Oct, 2030 | Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 24 Jun, 2030 | Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders | 24 Jun, 2030 | Active |
| US7919499 | Naltrexone long acting formulations and methods of use | 15 Oct, 2029 | Active |
| US7262298 | 4-hydroxybenzomorphans | 23 Nov, 2025 | Expired |
| US7956187 | Method for decreasing opioid metabolism | 31 Oct, 2021 | Expired |
| US8252929 | 8-carboxamido-2,6-methano-3-benzazocines | 31 Oct, 2021 | Expired |
| US6495164 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US7799345 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US6264987 | Method for preparing microparticles having a selected polymer molecular weight | 19 May, 2020 | Expired |
| US6379704 | Method for preparing microparticles having a selected polymer molecular weight | 19 May, 2020 | Expired |
| US6534092 | Method for preparing microparticles having a selected polymer molecular weight | 19 May, 2020 | Expired |
| US6331317 | Apparatus and method for preparing microparticles | 12 Nov, 2019 | Expired |
| US6395304 | Apparatus and method for preparing microparticles | 12 Nov, 2019 | Expired |
| US6495166 | Apparatus and method for preparing microparticles using in-line solvent extraction | 12 Nov, 2019 | Expired |
| US6537586 | Apparatus and method for preparing microparticles | 12 Nov, 2019 | Expired |
| US6713090 | Apparatus and method for preparing microparticles | 12 Nov, 2019 | Expired |
| US6939033 | Method and apparatus for preparing microparticles using in-line solvent extraction | 12 Nov, 2019 | Expired |
| US6194006 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US6379703 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US6596316 | Preparation of microparticles having a selected release profile | 30 Dec, 2018 | Expired |
| US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
| US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
| US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent | 02 May, 2017 | Expired |
Latest Legal Activities on Alkermes's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alkermes.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Jun, 2024 | US9526726 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9517235 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jun, 2024 | US10849894 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Apr, 2024 | US10813928 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US8252929 |
| Mail Patent eGrant Notification | 09 Apr, 2024 | US11951111 |
| Recordation of Patent eGrant | 09 Apr, 2024 | US11951111 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Apr, 2024 | US11951111 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Apr, 2024 | US11951111 |
| Patent eGrant Notification | 09 Apr, 2024 | US11951111 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11951111 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Mar, 2024 | US9452131 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11951111 |
|
Issue Notification Mailed
Critical
| 20 Mar, 2024 | US11951111 |
| Dispatch to FDC | 08 Mar, 2024 | US11951111 |
Alkermes's Drug Patent Litigations
Alkermes's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 31, 2016, against patent number US6667061. The petitioner Luye Pharma Group Ltd., challenged the validity of this patent, with Alkermes Controlled Therapeutics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Alkermes's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7919499 | January, 2025 |
Discretionary Denial
(02 Jul, 2025)
| Alkermes Pharma Ireland Limited | Apotex Inc. et al. |
| US7919499 | April, 2018 |
Terminated-Settled
(31 Jul, 2019)
| Alkermes Pharma Ireland Limited | Amneal Pharmaceuticals LLC |
| US6667061 | May, 2016 |
Final Written Decision
(28 Nov, 2017)
| Alkermes Controlled Therapeutics, Inc. et al. | Luye Pharma Group Ltd. et al. |
| US6667061 | May, 2016 |
FWD Entered
(28 Nov, 2017)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
| US6667061 | May, 2016 |
Institution Denied
(30 Nov, 2016)
| Alkermes Controlled Therapeutics, Inc. et al. | Luye Pharma Group Ltd. et al. |
| US6667061 | May, 2016 |
Terminated-Denied
(30 Nov, 2016)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
Alkermes Drug Patents' Oppositions Filed in EPO
Alkermes drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 24, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP12712189A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15750750A | Nov, 2019 | Generics (UK) Ltd | Patent maintained as amended |
| EP10792677A | Mar, 2018 | Generics (UK) Ltd | Patent maintained as amended |
| EP12712189A | May, 2017 | Generics (UK) Ltd | Opposition rejected |
Alkermes's Family Patents
Alkermes drugs have patent protection in a total of 36 countries. It's US patent count contributes only to 31.5% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alkermes Drug List
Given below is the complete list of Alkermes's drugs and the patents protecting them.
1. Aristada
Aristada is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273158 | Aripiprazole dosing strategy |
06 Apr, 2039
(13 years from now)
| Active |
| US12251381 | Aripiprazole dosing strategy |
06 Apr, 2039
(13 years from now)
| Active |
| US10238651 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(9 years from now)
| Active |
| US10813928 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(9 years from now)
| Active |
| US11406632 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(9 years from now)
| Active |
| US9452131 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(9 years from now)
| Active |
| US9526726 | Aripiprazole formulations having increased injection speeds |
19 Mar, 2035
(9 years from now)
| Active |
| US11097006 | Pharmaceutical compositions having improved storage stability |
24 Oct, 2033
(7 years from now)
| Active |
| US11969469 |
24 Oct, 2033
(7 years from now)
| Active | |
| US9193685 | Pharmaceutical compositions having improved storage stability |
24 Oct, 2033
(7 years from now)
| Active |
| US12311027 |
19 Sep, 2033
(7 years from now)
| Active | |
| US9034867 | Pharmaceutical compositions comprising sorbitan esters |
07 Nov, 2032
(6 years from now)
| Active |
| US10226458 | Pharmaceutical compositions comprising sorbitan esters |
19 Mar, 2032
(6 years from now)
| Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
26 Oct, 2030
(4 years from now)
| Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(4 years from now)
| Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada's drug page
2. Aristada Initio Kit
Aristada Initio Kit is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273158 | Aripiprazole dosing strategy |
06 Apr, 2039
(13 years from now)
| Active |
| US12251381 | Aripiprazole dosing strategy |
06 Apr, 2039
(13 years from now)
| Active |
| US10016415 | Aripiprazole prodrug compositions |
08 Sep, 2035
(9 years from now)
| Active |
| US10688091 | Aripiprazole prodrug composition |
17 Aug, 2035
(9 years from now)
| Active |
| US10849894 | Aripiprazole prodrug composition |
17 Aug, 2035
(9 years from now)
| Active |
| US11154552 | Aripiprazole prodrug composition |
17 Aug, 2035
(9 years from now)
| Active |
| US8431576 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
26 Oct, 2030
(4 years from now)
| Active |
| US10112903 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(4 years from now)
| Active |
| US8796276 | Heterocyclic compounds for the treatment of neurological and psychological disorders |
24 Jun, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada Initio Kit's drug page
3. Lybalvi
Lybalvi is protected by 17 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11707466 | Immediate release multilayer tablet |
12 Nov, 2041
(15 years from now)
| Active |
| US11951111 | Immediate release multilayer tablet |
12 Nov, 2041
(15 years from now)
| Active |
| US12390474 |
12 Nov, 2041
(15 years from now)
| Active | |
| US8778960 | Methods for treating antipsychotic-induced weight gain |
13 Feb, 2032
(6 years from now)
| Active |
| US9119848 | Morphinan derivatives for the treatment of drug overdose |
30 Aug, 2031
(5 years from now)
| Active |
| US10300054 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US10716785 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US11185541 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US11241425 | Composition for treating mental illness |
23 Aug, 2031
(5 years from now)
| Active |
| US11351166 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US11793805 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US12194035 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US9126977 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US9517235 | Methods for treating antipsychotic-induced weight gain |
23 Aug, 2031
(5 years from now)
| Active |
| US7262298 | 4-hydroxybenzomorphans |
23 Nov, 2025
(a month ago)
| Expired |
| US7956187 | Method for decreasing opioid metabolism |
31 Oct, 2021
(4 years ago)
| Expired |
| US8252929 | 8-carboxamido-2,6-methano-3-benzazocines |
31 Oct, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lybalvi's drug page
4. Vivitrol
Vivitrol is protected by 19 patents, out of which 18 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7919499 | Naltrexone long acting formulations and methods of use |
15 Oct, 2029
(3 years from now)
| Active |
| US6495164 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(5 years ago)
| Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(5 years ago)
| Expired |
| US7799345 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(5 years ago)
| Expired |
| US6264987 | Method for preparing microparticles having a selected polymer molecular weight |
19 May, 2020
(5 years ago)
| Expired |
| US6379704 | Method for preparing microparticles having a selected polymer molecular weight |
19 May, 2020
(5 years ago)
| Expired |
| US6534092 | Method for preparing microparticles having a selected polymer molecular weight |
19 May, 2020
(5 years ago)
| Expired |
| US6331317 | Apparatus and method for preparing microparticles |
12 Nov, 2019
(6 years ago)
| Expired |
| US6395304 | Apparatus and method for preparing microparticles |
12 Nov, 2019
(6 years ago)
| Expired |
| US6495166 | Apparatus and method for preparing microparticles using in-line solvent extraction |
12 Nov, 2019
(6 years ago)
| Expired |
| US6537586 | Apparatus and method for preparing microparticles |
12 Nov, 2019
(6 years ago)
| Expired |
| US6713090 | Apparatus and method for preparing microparticles |
12 Nov, 2019
(6 years ago)
| Expired |
| US6939033 | Method and apparatus for preparing microparticles using in-line solvent extraction |
12 Nov, 2019
(6 years ago)
| Expired |
| US6194006 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(7 years ago)
| Expired |
| US6379703 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(7 years ago)
| Expired |
| US6596316 | Preparation of microparticles having a selected release profile |
30 Dec, 2018
(7 years ago)
| Expired |
| US5792477 | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
| US5916598 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
| US6403114 | Preparation of biodegradable, biocompatible microparticles containing a biologically active agent |
02 May, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vivitrol's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List